Journal
SCHIZOPHRENIA BULLETIN
Volume 41, Issue 6, Pages 1224-1226Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbv117
Keywords
schizophrenia; biomarkers; antipsychotic; efficacy; cognition
Categories
Ask authors/readers for more resources
The Mental Health Centers for Intervention Development and Applied Research (CIDAR) program prioritized research to provide an evidence base for biomarker development. At the Zucker Hillside Hospital (ZHH), our CIDAR grant supported research on a comprehensive investigation of treatment response and outcome in first episode schizophrenia. Results provide evidence that baseline neuroimaging, neurocognitive, and genetic measures are significantly associated with clinical response to treatment, and that our currently available interventions can effectively treat aspects of psychotic illness, as well as potentially reduce comorbidity associated with illness. Future research may include combining modalities to more robustly predict response and identify treatment targets, as well as to further develop more effective intervention strategies for these devastating and disabling disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available